If the dopamine system is the headline of schizophrenia neuroscience, the prefrontal cortex is the longest-running storyline. The prefrontal cortex (PFC) underlies the higher-order cognitive functions most affected by schizophrenia — working memory, planning, attention, abstract reasoning, social cognition. It is also the region where the cellular abnormalities of the disorder have been described in the greatest detail.
In schizophrenia, the prefrontal cortex shows reduced grey matter volume, altered activation during cognitive tasks (often called "hypofrontality" though more accurately a problem of efficiency), and post-mortem reductions in dendritic spines and parvalbumin GABA interneurons.
What the prefrontal cortex does
The PFC sits at the front of the brain and is the most expanded region in humans relative to other primates. It includes the dorsolateral prefrontal cortex (DLPFC), implicated in working memory and executive function; the ventromedial prefrontal cortex (vmPFC), involved in valuation and decision-making; and the orbitofrontal cortex, involved in reward learning. The PFC is essential for holding information in mind, switching between tasks, inhibiting inappropriate responses, and integrating context.
Volume reductions: structural MRI
Structural MRI studies, including the ENIGMA Schizophrenia Working Group's cortical analyses published in Molecular Psychiatry (2018), show widespread cortical thinning in schizophrenia, with prominent reductions in frontal and temporal regions. The DLPFC, anterior cingulate, and superior temporal cortex are among the most affected. Volume reductions are present at first episode and progress modestly over time, especially in the early years of illness.
Cortical thickness reductions are not unique to schizophrenia — they overlap with other psychiatric conditions — but the pattern, especially in frontotemporal regions, is among the most reproducible structural features of the disorder.
"Hypofrontality" — the functional finding
One of the oldest functional findings in schizophrenia neuroscience, going back to early PET studies in the 1970s and 1980s by Ingvar, Weinberger, and others, is reduced PFC activation during cognitive tasks like the Wisconsin Card Sorting Test. This was originally described as "hypofrontality" — the PFC simply being less active.
Subsequent work refined the picture. In some tasks and at some difficulty levels, schizophrenia patients show more PFC activation than controls, not less, suggesting inefficient recruitment of cortical resources. The current view, supported by functional MRI studies including those of Karen Berman and Daniel Weinberger, is that the PFC in schizophrenia operates inefficiently — needing more activation to achieve worse performance, and failing to scale activation appropriately with task demand.
Post-mortem cellular findings
The schizophrenia PFC has been one of the most intensively studied tissues in psychiatric neuropathology. The Lewis lab at Pittsburgh has produced a particularly detailed picture. Key findings include:
- Reduced dendritic spine density on layer 3 pyramidal neurons in the DLPFC, reported in multiple post-mortem studies (Glantz and Lewis, 2000; Garey and colleagues; Konopaske and colleagues). Spines are the points of synaptic contact, and their reduction implies fewer cortical-cortical connections.
- Reduced parvalbumin-expressing GABA interneurons, especially the chandelier subtype, with reduced GAD67 expression. This affects the inhibitory gating that supports gamma oscillations and working memory.
- Reduced neuropil (the dense thicket of axons, dendrites, and synapses between cell bodies), without major reduction in neuron number — consistent with the volume reductions reflecting fewer connections rather than fewer cells.
Working memory and the PFC
Working memory — holding information online for short periods to use it — is central to PFC function and is one of the most consistently impaired cognitive domains in schizophrenia. Reduced parvalbumin interneuron function disrupts the gamma oscillations that are thought to support working memory representations. Imaging studies of working memory tasks like the n-back show altered DLPFC activation in patients, often correlated with task performance.
Dopamine and the PFC
While most attention to dopamine in schizophrenia focuses on the striatum, prefrontal dopamine matters too. The leading model — articulated by Anissa Abi-Dargham, Patricio O'Donnell, and others — is that schizophrenia involves too much dopamine in the striatum and too little in the PFC. The COMT enzyme, which metabolises prefrontal dopamine, has been studied as a candidate gene for cognitive variation in schizophrenia. Most current antipsychotics, by blocking D2 receptors, address the striatal side but do little for the PFC side, which is part of why cognitive and negative symptoms respond poorly to standard medications.
Implications for cognitive and negative symptoms
The PFC story explains, in part, why cognitive symptoms and negative symptoms are so disabling and so resistant to dopamine-blocking medications. The cellular and circuit changes in the PFC are not the kind of problem that more D2 blockade can fix. Treatments aimed at this circuit — cognitive remediation, glutamate-targeting drugs, repetitive transcranial magnetic stimulation (rTMS), and emerging GABA-modulating compounds — are an active research area.
Cognitive remediation
Cognitive remediation therapy uses computer-based exercises to train working memory, attention, and executive function. Meta-analyses suggest small to moderate benefits on cognition and on functional outcomes, especially when combined with vocational support. See our cognitive remediation overview.
What the PFC story does not explain
Like the hippocampus and the thalamus, the PFC is part of a network problem. Hallucinations and delusions arise from striatal and other systems more than from the PFC alone. The PFC story is most useful for understanding what most disables people long-term — the cognitive and motivational difficulties that persist even when positive symptoms are controlled.
Direct-to-consumer brain stimulation devices are not validated for the treatment of schizophrenia. Any neuromodulation should be done under clinical supervision in a research or specialised setting.
The bottom line
The prefrontal cortex is structurally thinner, functionally less efficient, and cellularly altered in schizophrenia. These changes underlie much of the cognitive and motivational disability that persists across the illness. They also help explain why current dopamine-focused treatments leave so many people partially recovered. The next generation of schizophrenia therapeutics — and the field's best hope for meaningfully improving long-term function — will likely address the PFC more directly than current medications do.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.